{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"AGEN-1181"},{"type":"CodeName","name":"AGEN1181"},{"type":"CodeName","name":"AGEN 1181"},{"type":"Synonym","name":"anti-CTLA-4 monoclonal antibody AGEN1181"},{"type":"CASRegistryName","name":"2408310-37-0"}],"definition":{"html":"An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.","text":"An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody."},"drugInfoSummaryLink":null,"nciConceptId":"C158557","nciConceptName":"Botensilimab","termId":797474,"name":"botensilimab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"botensilimab"}],"links":null}